For the quarter ending 2026-03-31, TRDA made $875K in revenue. -$40,123K in net income. Net profit margin of -4585.49%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 875 | -7,837* | 1,614 | - |
| Research and development | 33,054 | 24,080* | 38,361 | - |
| General and administrative | 10,124 | 10,183* | 10,304 | - |
| Total operating expenses | 43,178 | 34,263* | 48,665 | - |
| Loss from operations | -42,303 | -42,100* | -47,051 | - |
| Interest and other income | 2,624 | 3,054 | 3,571 | - |
| Total other income | 2,624 | 3,054* | 3,571 | - |
| Loss before provision for income taxes | -39,679 | -39,046 | -43,480 | -42,925 |
| Provision for income taxes | 38 | 118 | 654 | 178 |
| Net loss | -39,717 | -39,164 | -44,134 | -43,103 |
| Unrealized (loss) gain on marketable securities | -406 | 31 | 221 | -37 |
| Total other comprehensive (loss) gain | -406 | 31 | 221 | -37 |
| Total comprehensive loss | -40,123 | -39,133 | -43,913 | -43,140 |
| Basic EPS | -0.95 | -0.94 | -1.06 | -1.04 |
| Diluted EPS | -0.95 | -0.94 | -1.06 | -1.04 |
| Basic Average Shares | 41,836,275 | 41,610,893 | 41,462,567 | 41,338,752 |
| Diluted Average Shares | 41,836,275 | 41,610,893 | 41,462,567 | 41,338,752 |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)